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Bacterial infection remains one of the leading causes of death worldwide, and the
options for treating such infections are decreasing, due the rise of antibiotic-resistant
bacteria. The pharmaceutical industry has produced few new types of antibiotics in
more than a decade. Researchers are taking several approaches toward developing
new classes of antibiotics, including (1) focusing on new targets and processes, such
as bacterial cell–cell communication that upregulates virulence; (2) designing inhibitors
of bacterial resistance, such as blockers of multidrug efflux pumps; and (3) using
alternative antimicrobials such as bacteriophages. In addition, the strategy of finding
new uses for existing drugs is beginning to produce results: antibacterial properties have
been discovered for existing anticancer, antifungal, anthelmintic, and anti-inflammatory
drugs. In this review, we discuss the antimicrobial properties of gallium compounds,
5-fluorouracil, ciclopirox, diflunisal, and some other FDA-approved drugs and argue
that their repurposing for the treatment of bacterial infections, including those that are
multidrug resistant, is a feasible strategy.
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Introduction
New Approaches to Combat Bacterial Infections on the Verge of the
Post-Antibiotic Era
Since the pharmaceutical industry has not produced a new class of antibiotics for more than a
decade (Walsh and Wencewicz, 2014) and the continuing rise of antibiotic resistance is a major
health concern, the World Health Organization warned that we may enter a “post-antibiotic era”
within this century, and they propose that urgent actions be taken (Aryee and Price, 2014). In
addition, a recent estimate by the British government and the Welcome Trust warned that by
the year 2050 there will be 300 million premature deaths and up to £64 trillion lost to the global
economy due to bacterial infections. Therefore, research is now being directed toward (1) new
types of antimicrobials, such as peptides (Seo et al., 2012), (2) novel therapeutic agents like bac-
teriophages (Abedon et al., 2011; Chan et al., 2013), (3) inhibiting bacterial virulence by blocking
quorum sensing (QS; Kaufmann et al., 2008; Antunes et al., 2010; Rasko and Sperandio, 2010), and
(4) targeting systems that confer resistance against antibiotics, such as multidrug eﬄux pumps
(Lomovskaya and Watkins, 2001; Kaatz, 2002). Each of these approaches has faced signiﬁcant
diﬃculties. Antimicrobial peptides are expensive, toxic, and subject to proteolysis (Seo et al., 2012);
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bacteriophages are attacked by the immune system, and bacteria
soon develop resistance to them (Brussow, 2012); and resistance
against canonical QS inhibitors is possible (Maeda et al., 2012;
García-Contreras et al., 2013b,c; Kalia et al., 2014).
Another approach to dealing with bacterial infections is to
repurpose existing drugs as antibiotics or virulence inhibitors.
This approach has several advantages, including avoiding the
high costs and long development times for producing new
antimicrobials, and also being able to utilize compounds with
known pharmacological properties, and as is discussed here (see
also Table 1), although the approach to ﬁnd alternative antimi-
crobials by evaluating drugs with other approved uses is relatively
new, there are at least a tens of feasible candidates with promising
in vitro and in vivo (at least for some of them) antibacterial prop-
erties, being the diversity of the active compounds remarkable
and their molecular targets diverse, and in some cases unex-
ploited by conventional antimicrobials, it can be anticipated that
a more extensive search for ideal candidates will continue to iden-
tify several yet undiscovered promising drugs, in fact recently,
the UK and US launched programs to study de-prioritized drugs
to ﬁnd new therapeutic uses for them (Mullard, 2012). In this
work we discuss the antimicrobial eﬀects of attractive anticancer,
anti-fungal, and anti-inﬂammatory drugs and argue that at least
some of them are ideal candidates for repurposing as antibacterial
agents, while others deserve further in vitro and in vivo research
to fully evaluate their antibacterial potential.
Anticancer Drugs as Antimicrobials
Due the similarities between cancer cells and pathogenic bacteria
it is expected that some anti-neoplastics would be also eﬀec-
tive against bacteria. In fact, the anticancer drugs daunorubicin
and doxorubicin were originally isolated in 1939 as antibiotics.
Nevertheless, they were found to be too toxic to be used for
infections. In 1960, however, their antitumor properties were dis-
covered (Weiss, 1992), and they are now utilized for the treatment
of cancer. By the same token, some drugs that were originally
developed as anti-neoplastics are eﬀective at attenuating growth
of microbial pathogens, and some of them have shown promising
results in animal models and clinical trials. In the following sec-
tion, the antimicrobial properties of gallium and 5-ﬂuorouracil
are discussed.
Gallium
Gallium, a group IIIA element, has no known essential biolog-
ical function but displays diverse biological activities. Many of
gallium’s activities derive from its chemical similarities to ferric
iron (Fe3+): Ga3+ and Fe3+ have remarkably similar ionic radii,
electronegativities, electron, and ligand aﬃnities, and coordina-
tion geometries (Bernstein, 1998). This allows Ga3+ to follow
many of the uptake and transport pathways for Fe3+. It is the
diﬀerences between Ga3+ and Fe3+, however, that are responsi-
ble for gallium’s therapeutic eﬀects and low toxicity. Unlike Fe3+,
which is easily reduced to a divalent state, Ga3 cannot partic-
ipate in redox reactions under physiologic conditions. Ga will
therefore not function in enzymes requiring iron, and will not
become incorporated in heme, avoiding toxicity from interfer-
ence with oxygen transport and cytochrome-mediated reactions
(Hedley et al., 1988). Clinically, citrated Ga(NO3)3 for intra-
venous injection (Ganite R©) is approved for use for the treatment
of hypercalcemia of malignancy.
Gallium in the Treatment of Cancer
In 1951 it was shown that 72Ga could be used for the early detec-
tion and palliative treatment of bone malignancies. In the 1970s,
with the introduction of the radioisotope 67Ga, diagnostic gallium
scintigraphy became widespread. 67Ga-scans are particularly sen-
sitive to lymphomas, sarcomas, bone tumors, and hepatocellular
carcinoma. Many of the 67Ga-avid cancers appear to be those
that are most susceptible to therapeutic Ga treatment (Bernstein,
2013). Currently, 67Ga scanning is used in the diagnosis and stag-
ing of lymphomas. Ga(NO3)3 has demonstrated clinical eﬃcacy
in multiple myeloma, bladder cancer, lymphoma, ovarian cancer,
and hepatocellular carcinoma (Bernstein, 1998; Bernstein et al.,
2011).
Gallium Compounds have Potent
Antimicrobial Effects
The recognition of gallium as an antimicrobial was made in 1931
when it was used to treat experimental syphilis in rabbits and try-
panosomiasis in mice (Levaditi et al., 1931). Surprisingly, there
was a gap of more than 40 years until Ga was again reported to
have antimicrobial activity (Srivastava et al., 1973). The antibac-
terial activity of Ga compounds both in vitro and in vivo has now
been demonstrated against several important bacterial pathogens,
such as Mycobacterium tuberculosis, Pseudomonas aeruginosa
(Kaneko et al., 2007), Acinetobacter baumannii (Antunes et al.,
2012; de Leseleuc et al., 2012), and Staphylococcus aureus. For
a detailed description of gallium’s antibacterial eﬀects, see the
recent reviews by (Bernstein, 2013; Bonchi et al., 2014; Minandri
et al., 2014) and Table 2.
Mechanisms of Antimicrobial Activity for
Gallium
Gallium is a non-redox Fe (III) analog that acts as a “Trojan
horse” due to its chemical similarity to Fe(III). In Menon et al.
(1978) reported that Ga is taken up by several bacteria and
fungi. Later it was shown that Pseudomonas ﬂuorescens inter-
nalized Ga (Al-Aoukaty et al., 1992) and it was suggested that
the transport of Ga into P. aeruginosa does not involve its main
iron transporters, the siderophores pyoverdine and pyochelin
(Kaneko et al., 2007); although recently it was discovered that
the pyochelin system is likely able to transport moderate gal-
lium concentrations (Frangipani et al., 2014). In addition, Ga
inhibits Fe(III) transport through interference with pyoverdine:
by decreasing its production, through interference with the pvdS
sigma factor, and by directly binding pyoverdine and hence
decreasing Fe(III) uptake (Kaneko et al., 2007).
Currently, other than pyochelin, HitAB is the only Ga trans-
porter known in P. aeruginosa (García-Contreras et al., 2013a).
However, hitA/hitBmutants of P. aeruginosa still can take up Ga,
suggesting the existence of secondary Ga transporters (García-
Contreras et al., 2013a), Although pyochelin delivers iron trough
the outer membrane transporter, FptA, the possibility that it also
internalizes it via the HitB membrane protein remains to be
Frontiers in Microbiology | www.frontiersin.org 2 April 2015 | Volume 6 | Article 282
Rangel-Vega et al. Drug repurposing for bacterial infections
TABLE 1 | New strategies to combat bacterial infections.
Strategy Examples Advantages Disadvantages
Develop new
antibiotics
Daptomycin
Novel oxazolidinone
antibacterial agents
Optimized for inhibiting bacterial growth Only two new clasess of antibiotics had
been developed in the past 20 years
Not a priority for the pharmaceutical
companies
Scaffolds are scarce
Develop new types of
antimicrobials
Antimicrobial peptides
Bacteriophages
New targets, new action mechanisms Antimicrobial peptides: expensive, toxic,
and subject to proteolysis
Bacteriophages: attacked by the immune
system, prone to develop resistance
Develop new
anti-virulence drugs
Quorum sensing inhibitors
Inhibitors of bacterial
secretion systems
Targeting virulence instead of growth potentially could
decrease resistance
Quorum sensing inhibitors: resistance
mechanisms had been found
Not effective against some clinical strains
Target resistance
mechanisms
Multidrug efflux pumps
inhibitors
Will allow the re-utilization of already non-effective antibiotics Bacteria usually have several
simultaneous drug resistance
mechanisms
Drug repurposing for
antibacterial and
anti-virulence drugs
Ga containing compounds
5-FU
Ciclopirox
Diflunisal
Statins
Pentetic acid
Avoiding the high costs and long development times of novel
antimicrobials
Known pharmacological properties, known side effects, doses,
interactions with other drugs, etc
New targets, new action mechanisms
Ample repertoire, high versatility
Effective against several recalcitrant pathogens, including
MDR.
Not optimized for antibacterial or
antivirulence effects
Ga containing compounds: their broad
spectrum activity could be
counterproductive damaging healthy
host tissues, particularly fast growing
cells with high iron acquisition
5-FU: high toxicity
explored. Due to its similarity to iron, it is hypothesized that Ga
inhibits several Fe-redox dependent processes, such as iron trans-
port, respiration, DNA replication, and reactive oxygen species
(ROS) protection. Inhibition of Fe(III) transport by Ga was ﬁrst
demonstrated for intraphagosomal M. tuberculosis (Olakanmi
et al., 2000). The same group demonstrated that for Francisella
novicida and Francisella tularensis, Ga inhibits iron acquisition
from lactoferrin or transferrin in vitro and in vivo inmacrophages
(Olakanmi et al., 2010). Regarding the eﬀects of Ga on protection
against ROS, it was shown that for F. tularensis, the addition of
10 μM Ga-transferrin or Ga-lactoferrin decreased up to 70% the
activity of Fe-containing catalase and Fe-cofactored SOD, render-
ing the cells more sensitive to H2O2. In P. ﬂuorescens, prolonged
exposure to Ga decreased the iron content in catalase and its
activity (Beriault et al., 2007). Also, for P. ﬂuorescens, Ga dis-
rupted oxidative phosphorylation by inhibiting the respiratory
complexes. In addition, Ga inactivated aconitase and fumarase
A, two Fe-dependent enzymes (Chenier et al., 2008). The eﬀects
of Ga on the global metabolism of P. aeruginosa were recently
investigated by metabolomics: 64 metabolites showed signiﬁcant
changes between Ga-free and Ga-citrate cells (Rzhepishevska
et al., 2011).
Due to the very promising antibacterial eﬀects of Ga, the
repurposing of Ga(NO3)3 and other Ga compounds for treat-
ing MDRbacterial infections has been suggested recently (Bonchi
et al., 2014). In addition, considerable progress has been recently
made in the development of Ga delivery technologies, developing
materials like gallium-doped phosphate-based glasses (Valappil
et al., 2009) and gallium-carboxymethyl cellulose (Valappil et al.,
2013). These materials enable controlled Ga release and are
eﬀective at killing P. aeruginosa and, in the case of the glasses,
other important pathogens such as MRSA and Clostridium
diﬃcile. Other promising biomaterials that incorporate gallium
are mesoporous bioactive glass scaﬀolds (Shruti et al., 2013),
Ga-containing phosphosilicate glasses (Franchini et al., 2012;
Lusvardi et al., 2013) and Ga grafted titanium implants which
decrease bioﬁlm formation of oral bacteria such as Streptococcus
mutans (Cochis et al., 2015). Such novel materials may eventu-
ally be used in other clinical applications, for example to coat
catheters and medical prosthetic devices.
Bacterial Adaptation and Resistance to
Gallium
One of the main mechanisms of gallium’s antibacterial activity
may be the generation of ROS (Beriault et al., 2007; Chitambar,
2010). Consistent with this eﬀect, P. ﬂuorescens exposed to 1 mM
Ga-citrate has high amounts of oxidized lipids and proteins.
Such cells, however, respond to Ga by increasing the synthe-
sis of enzymes that produce NADPH and by increasing SOD
(Beriault et al., 2007). An increase in NADPH would provide the
reductive power for the detoxiﬁcation of ROS by glutathione per-
oxidase/reductase (Perry et al., 1991) and would protect catalase
from inactivation by H2O2 (Kirkman et al., 1999). In addition, in
the presence of Ga, P. ﬂuorescens compensates for the loss of its
fumarase A activity by overexpressing Fe-independent fumarase
C. In order to maintain the oxidation of NADH, an NADH oxi-
dase that is absent in the control cells is induced (Chenier et al.,
2008). Also, pyocyanin overexpression helps cells cope with Ga
toxicity (García-Contreras et al., 2013a). This protection may be
due its capacity to reduce Fe(III) to Fe(II), which would not be
aﬀected by Ga competition. Accordingly, lower concentrations of
Fe(II) than of Fe(III) are needed to protect the cells against Ga
(García-Contreras et al., 2013d). This fact may be clinically rele-
vant, since Fe(II) is increasingly available to P. aeruginosa during
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TABLE 2 | Antibacterial activities of the reviewed drugs.
Drug Therapeutic use Antibacterial activity in vitro Antibacterial activity in vivo Reference
Gallium compounds Gallium nitrate: treatment of
hypercalcemia of malignancy
Growth inhibition of several
recalcitrant bacterial pathogens
(including clinical isolates) such as:
Gram (−) Pseudomonas aeruginosa y
A. baumanii and Gram (+) like
Mycobacterium tuberculosis
Effective against syphilis
(Treponema cuniculi) in rabbits
and trypanosomiasis in mice,
guinea pigs, and monkeys
Acute and chronic mice
infections of P. aeruginosa
A. baumannii infections in
caterpillar and mice
Levaditi et al. (1931),
Olakanmi et al. (2000),
Kaneko et al. (2007), DeLeon
et al. (2009), Antunes et al.
(2012), de Leseleuc et al.
(2012)
5-Florouracil Anticancer drug
Treatment of actinic keratosis
and Bowen’s disease
Growth inhibition of Gram (+) and (−)
bacterial species
Inhibition of biofilm formation
Repression of QS in P. aeruginosa
Successful in clinical trials in
humans, as external coating of
central venous catheters
Hussain et al. (1992), Ueda
et al. (2009), Walz et al.
(2010)
Ciclopirox Antifungal Bacteriostatic and bactericide activity,
depending on concentration used, in
laboratory and clinical isolates
Not yet tested Carlson-Banning et al. (2013)
5-fluorocytosine Antifungal Inhibition of virulence factor
production by P. aeruginosa
Suppresses P. aeruginosa
pathogenicity in a mouse
model of lung infection
Imperi et al. (2013a)
Azithromycin Antibiotic Inhibition of QS systems of P.
aeruginosa
Clinical evidence and clinical
trials demonstrate efficacy in
the treatment of chronic
pulmonary infections of P.
aeruginosa
Imperi et al. (2014)
Niclosamide Antihelmintic Inhibition of QS systems of P.
aeruginosa
Reduction of P. aeruginosa
pathogenicity in an insect
model
Imperi et al. (2013b)
Diflunisal Non-steroidal anti-inflammatory Potent virulence inhibitor for the
USA300 strain of methicillin-resistant
Staphylococcus aureus (MRSA)
Not yet tested Khodaverdian et al. (2013)
Statins Lower plasma cholesterol levels Reduction of virulence factor
production of P. aeruginosa
Broad spectrum antibacterial effects
Inhibition of S. pneumoniae
attachment to lung and
vascular tissue
Rosch et al. (2010)
Pentetic acid Preparation of
radiopharmaceuticals treatment
of iron-storage disease and
poisoning from heavy metals
Reduction of virulence factor
production of P. aeruginosa
Effective to alleviate mice
airway infections
Gi et al. (2014)
Terfenadine Antihistamine Inhibit growth of several pathogenic
bacteria, including S. aureus and M.
tuberculosis
Not yet tested Perlmutter et al. (2014)
Zafirlukast Treatment of asthma Antimycobacterial Not yet tested Pinault et al. (2013)
the course of an infection, and it promotes pulmonary infections
in CF patients (Hunter et al., 2013).
Moreover, the overexpression of the siderophore pyover-
dine in P. aeruginosa may also promote gallium resistance,
since it is likely able to sequester extracellular Ga, prevent-
ing its entrance to the cell. Adding pyoverdine to cultures
increases their Ga tolerance (Kaneko et al., 2007; Frangipani
et al., 2014). In contrast, it was recently demonstrated that the
disruption of pyochelin biosynthesis and uptake increases the
MIC50 for gallium two–fourfold in the P. aeruginosa PAO1
strain (Frangipani et al., 2014). Interestingly, restricting gallium’s
growth inhibitory eﬀects by pyoverdine sequestration strongly
decreases the development of bacterial resistance (Ross-Gillespie
et al., 2014).
Another important property of Ga compounds is that
they modulate the expression of several virulence factors in
P. aeruginosa. For example, they decrease the expression of
pyoverdine (Kaneko et al., 2007; García-Contreras et al., 2013d).
Depending in the growth conditions, concentrations, and per-
haps on the particular gallium compound, gallium can either
decrease (Kaneko et al., 2007; Valappil et al., 2013) or promote
(García-Contreras et al., 2013d) bioﬁlm formation. Although
the molecular processes involved in the modulation of viru-
lence factors by gallium are still unknown, gallium’s role may
be related to its ability to create a state of iron deﬁciency, since
iron starvation strongly promotes virulence (García-Contreras
et al., 2013d). Although Ga has proven eﬀective to alleviate
diverse animal infections, whether growth sub-inhibitory con-
centrations can promote bacterial virulence in vivo remains
unexplored.
There is thus substantial evidence demonstrating that gallium
compounds have a broad spectrum of antibacterial activity, and
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their mechanisms of action are fairly well deﬁned. Clinical trials
to test Ga(NO3)3 in patients with cystic ﬁbrosis are being con-
ducted at the University of Washington; these trials are being
designed to assess the pulmonary safety of the compound and its
eﬃcacy in improving lung function and decreasing P. aeruginosa
counts.
5-Fluorouracil
The uracil analog 5-ﬂuorouracil (5-FU) is an antimetabolite
developed in by Heidelberger et al. (1957). Twenty years later,
clinical trials conﬁrmed that 5-FU was an eﬀective anticancer
drug. To date, 5-FU is widely used in the clinic, being applied sys-
temically to treat gastrointestinal adenocarcinoma and squamous
cell carcinoma, or as adjuvant chemotherapy for breast carcinoma
and others. It is also applied topically to treat actinic keratosis,
superﬁcial basal cell carcinoma, and Bowen’s disease.
5-Fluorouracil as an Antibacterial,
Antibiofilm, and Virulence Inhibitor
In 1985, it was shown that 5-FU had potent antimicrobial eﬀects
against several bacterial pathogens. It was then conﬁrmed that 5-
FU inhibited the growth of S. aureus and S. epidermidis, with an
MIC50 ≤0.8 μg/mL, and that it acts synergistically against Gram
(−) bacteria when combined with beta-lactamics (Gieringer et al.,
1986). Later, it was found that it is synergistic with tobramycin
against S. aureus (Nyhlen et al., 2002) and that it inhibits S.
epidermidis bioﬁlms (Hussain et al., 1992).
Unlike conventional antimicrobials, which act by directly
aﬀecting bacterial growth and survival, anti-virulence therapies
are designed to decrease the potential damage produced by the
pathogens to the host, hence reducing the chances for the devel-
opment of resistance (Rasko and Sperandio, 2010). In this regard,
it was found that because uracil biosynthesis is important for QS,
swarming, bioﬁlm formation, and production of QS-controlled
virulence factors (Ueda et al., 2009), 5-FU is an eﬀective repres-
sor of QS and bioﬁlms without having a severe inhibitory eﬀect
on growth, and was able to protect barley against P. aerug-
inosa infection. The reduction of P. aeruginosa pathogenicity
by 5-FU was also later reported by Imperi et al. (2013a) when
they demonstrated that 5-ﬂuorocytosine, which is converted to
the active compound 5-FU, also reduces pyoverdine, PrpL pro-
tease, and exotoxin A, and suppresses P. aeruginosa pathogenicity
in murine lung infections. 5-FU is also able to inhibit bioﬁlms
and virulence of enterohemorrhagic Escherichia coli (Attila et al.,
2009). Remarkably, in Walz et al. (2010) 5-FU was used in
large-scale human trials as an anti-infective external coating of
central venous catheters, producing better results than the pos-
itive controls chlorhexidine and silver sulfadiazine. It was thus
demonstrated that 5-FU provides a safe and eﬀective coating on
catheters for critically ill patients (Walz et al., 2010).
The eﬀect in 5-FU during bacterial infections in vivo probably
would be dual, targeting both the production of virulence factors
and bioﬁlms as well as bacterial growth. Toxicity to bacteria likely
will depend on the available nutrients, particularly uracil, since
in vitro in rich culture medium (with 0.2 mM of uracil), P. aerug-
inosa can grow well with 25–50 μM of 5-FU (Ueda et al., 2009;
García-Contreras et al., 2013c), while similar concentrations of
5-FU are able to prevent its growth in minimal medium with no
added uracil (West and Chu, 1986).
5-Fluorouracil Action Mechanisms and
Resistance in Bacteria
Although the eﬀects of 5-FU as an anticancer drug are well
known, its eﬀects as an antibacterial have not been extensively
studied. In 1961, one study showed that 5-FU inhibits ribo-
some and protein synthesis in Mg-deprived bacteria. In fungi,
5-FU is transformed to 5-ﬂuorouridine triphosphate (FUTP)
and then incorporated into RNA instead of uridylic acid, alter-
ing the amino-acylation of tRNA, disturbing the amino acid
pool and inhibiting protein synthesis (Waldorf and Polak,
1983; Vermes et al., 2000). In addition, 5-FU is also converted
into 5-ﬂuorodeoxyuridine monophosphate (FdUMP), a potent
inhibitor of thymidylate synthetase, an enzyme essential for the
generation of thymidine, and its inhibition prevents DNA syn-
thesis (Vermes et al., 2000).
Although the mechanisms of action for 5-FU against QS and
bioﬁlms are largely unknown, inhibition of E. coli bioﬁlm forma-
tion by 5-FU requires the presence of AriR (Attila et al., 2009),
which binds DNA and supresses bioﬁlms (Lee et al., 2007). Not
surprisingly, along with the lack of mechanistic studies about 5-
FU’s eﬀects on bacteria, studies of adaptation and resistance to
it are scarce. Recently, however, it was shown that although 5-
FU inhibits the QS-controlled virulence factor production of P.
aeruginosa, some clinical strains are resistant (García-Contreras
et al., 2013c).
Similarly to gallium compounds, 5-FU has broad spectrum
antimicrobial activity and inhibits virulence factor and bioﬁlm
production. Since it had been shown eﬀective at preventing
microbial colonization of catheters in human trials, we expect
that it could be eventually implemented for this purpose, and that
other possible uses, such as a topical or systemic antibiotic, could
be tested in animal models soon.
Repurposing Antibiotics as Virulence
Inhibitors
Interestingly, several diﬀerent antibiotics, particularly macrolides
such as azithromycin but also ceftazidime (CFT) and
ciproﬂoxacin, are able to decrease the expression of QS
controlled virulence factors of P. aeruginosa, and azithromycin
has improved the clinical outcome of chronically infected cystic
ﬁbrosis patients (Skindersoe et al., 2008). In addition, this
antibiotic has anti-inﬂammatory properties and is considered
an ideal candidate for repurposing as an anti-virulence agent.
For a detailed description of azithromycin as an anti-virulence
drug, see (Imperi et al., 2014). It is also noted that ciproﬂoxacin,
metronidazole, and tinidazole may interfere with QS in vivo
when used to treat Crohn’s disease (Struss et al., 2012).
Antifungals and Other Types of Drugs
Some antifungal drugs also have potent antibacterial activity.
Deng and collaborators identiﬁed a compound with broad-
spectrum antibacterial activity, which later led to the identiﬁ-
cation of ciclopirox as an antibacterial, by a structural based
search (Carlson-Banning et al., 2013). Ciclopirox is an oﬀ-patent,
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topical antifungal developed 40 years ago. It is notable for its
excellent safety proﬁle; also, unlike many antifungals, no fun-
gal resistance to it has been identiﬁed (Subissi et al., 2010),
which is remarkable. The antifungal mechanism of ciclopirox
remains unknown, though it is known to not inhibit ergos-
terol biosynthesis (Niewerth et al., 2003), and likely interferes
with iron metabolism (Sigle et al., 2005). Ciclopirox has potent
bacteriostatic activity against laboratory and clinical isolates
of E. coli, including ciproﬂoxacin resistant isolates, with an
MIC50 of 5–15 μg/mL; at higher concentrations, it acts as
bactericide. Moreover, it also inhibits growth of A. bauman-
nii, Klebsiella pneumoniae, P. aeruginosa (including MDR iso-
lates), and Proteus mirabilis. The activity of ciclopirox against
E. coli involves interference with galactose metabolism and
disruption of LPS biosynthesis. For P. aeruginosa, ciclopirox
inhibits pyocyanin and may increase pyoverdine production
(Carlson-Banning et al., 2013).
The anthelmintic drug niclosamide inhibits P. aeruginosa’s
production of acyl-homoserine lactone, QS signaling molecules,
and QS-regulated virulence factors. Niclosamide reduced bioﬁlm
formation and motility, preventing P. aeruginosa pathogenicity
in insects (Imperi et al., 2013b). Similarly, the non-steroidal anti-
inﬂammatory drug diﬂunisal is a potent virulence inhibitor for
the USA300 strain of methicillin-resistant S. aureus. It inhibits the
production of alpha-hemolysin andmodulin αwithout inhibiting
growth (Khodaverdian et al., 2013). In addition, statins, which
lower plasma cholesterol levels, also reduce virulence factors of
P. aeruginosa when used at 10–100 μM (Hennessy et al., 2012),
in vivo attachment of S. pneumoniae to lung and vascular tissue at
1 μM (Rosch et al., 2010) and have broad spectrum antibacterial
eﬀects at relatively high concentrations 15–600 μM (Hennessy
et al., 2012), making them additional candidates for repurposing
as antibacterial agents. Nevertheless, the antibacterial properties
of these drugs have still not been demonstrated in mice or other
mammals, and no clinical trials have been conducted.
Other interesting compounds with potential to be repurposed
as anti-virulence drugs are: (1) pentetic acid, a chelating agent
used in the preparation of radiopharmaceuticals and to treat iron-
storage disease and poisoning from heavy metals, which is able
to decrease elastase activity, PQS production, and bioﬁlm for-
mation of P. aeruginosa (Gi et al., 2014); (2) the antihistamine
terfenadine, which inhibits bacterial type II topoisomerases and
thus has potent antimicrobial activity against S. aureus,M. tuber-
culosis and other bacterial pathogens (Perlmutter et al., 2014);
and (3) zaﬁrlukast, a leukotriene receptor antagonist used in the
prophylactic treatment of asthma, which inhibits growth of M.
tuberculosis by blocking complex formation between the pro-
tein Lsr2 and DNA, hence interfering with the condensation and
structural organization of the bacterial genome; interestingly, this
drug target is novel since no current anti-mycobacterial agent is
directed against it (Pinault et al., 2013).
Concluding Remarks
Based on the evidence discussed (summarized in Table 2), there
are currently several drugs in clinical use for other indications
that have demonstrated in vitro eﬃcacy at inhibiting the growth
and/or virulence of bacterial pathogens. These drugs are struc-
turally very diverse and have a very broad spectrum of clinical
uses. Most of these drugs show activity against clinical isolates,
including those that are multidrug resistant and already practi-
cally untreatable, such as MDR isolates of P. aeruginosa (Poole,
2011), A. baumannii, and other recalcitrant bacterial pathogens
(Livermore, 2009); moreover, some of them have alleviated infec-
tions in animal models and the possible ways bacteria may adapt
and develop resistance against some of the most promising drug
candidates is at least partially known. 5-ﬂuorouracil has shown
remarkable antibacterial eﬃcacy in clinical trials, while the other
very promising drug candidates, including gallium compounds,
are either still awaiting or are just beginning human clinical
antibacterial testing.We propose that these compounds represent
new opportunities in the battle against increasingly antibiotic-
resistant bacteria, and we encourage the research and medical
communities to further advance their implementation as antibac-
terial drugs in the clinic. We also encourage the evaluation of
as-yet untested drugs as potential antimicrobial and antivirulence
compounds: we feel this is a fertile ﬁeld to ﬁnd new antimicrobials
that could be brought quickly into clinical use. Although some
potential diﬃculties and disadvantages of repurposing drugs exist
(see Table 1), drug repurposing may be the only feasible alter-
native to eﬀectively treat bacterial infections in a relatively short
period of time, before we have to return to a pre-antibiotic era.
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